
    
      This is an phase IV open-label, multicenter, single-arm clinical trial in. A total of 600
      cases were planned to be recruited. These cases were given simplified therapy regimen of
      lopinavir (200mg) and ritonavir (50mg) (500mg, oral, bid ) combined with lamivudine (300mg,
      oral, qd. The observation duration is thirty-sixth months. Patients will be followed up
      before and 12, 24 and 36 months after receiving the simplified regimen, observing the viral
      inhibition rate and the change of CD4 cell count, the safety and patients'compliance.
    
  